As on Wednesday, Nurix Therapeutics Inc (NASDAQ: NRIX) started slowly as it slid -3.34% to $18.21, before settling in for the price of $18.84 at the close. Taking a more long-term approach, NRIX posted a 52-week range of $8.18-$22.50.
It was noted that the giant of the Healthcare sector posted annual sales growth of -38.86% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -38.86%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -8.31%. This publicly-traded company’s shares outstanding now amounts to $101.37 million, simultaneously with a float of $99.81 million. The organization now has a market capitalization sitting at $1.85 billion. At the time of writing, stock’s 50-day Moving Average stood at $14.01, while the 200-day Moving Average is $11.69.
Nurix Therapeutics Inc (NRIX) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Nurix Therapeutics Inc’s current insider ownership accounts for 1.53%, in contrast to 82.45% institutional ownership. According to the most recent insider trade that took place on Nov 24 ’25, this organization’s Chief Legal Officer sold 37,600 shares at the rate of 17.07, making the entire transaction reach 641,697 in total value, affecting insider ownership by 50,897.
Nurix Therapeutics Inc (NRIX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
Nurix Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -8.31% and is forecasted to reach -3.31 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -4.26% through the next 5 years, which can be compared against the -38.86% growth it accomplished over the previous five years trading on the market.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Let’s observe the current performance indicators for Nurix Therapeutics Inc (NRIX). It’s Quick Ratio in the last reported quarter now stands at 5.35. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 22.06.
In the same vein, NRIX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.97, a figure that is expected to reach -0.92 in the next quarter, and analysts are predicting that it will be -3.31 at the market close of one year from today.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Through scrutinizing the latest numbers posted by the [Nurix Therapeutics Inc, NRIX], it can be observed that its last 5-days Average volume of 1.84 million was better the volume of 1.09 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 32.74% While, its Average True Range was 53.31.
Raw Stochastic average of Nurix Therapeutics Inc (NRIX) in the period of the previous 100 days is set at 70.01%, which indicates a major rise in contrast to 33.80% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.23 that was higher than 0.75 volatility it exhibited in the past 100-days period.
